
AI-driven biotech firm speeding up drug design for various diseases.
Founded with the mission to revolutionize drug development, 1910 Genetics integrates AI, computation, and biological automation to design small molecule and protein therapeutics. The company aims to reduce the time and cost associated with drug development while increasing the success rate of bringing innovative medicines to patients. Their proprietary drug discovery engines, ELVIS™ and ROSALYND™, enable the design of both small molecule and protein therapeutics, making them a unique player in the AI-driven biotech space.
Notable figures affiliated with 1910 Genetics include its leadership team and key investors from leading pharmaceutical and technology sectors. The company has achieved significant milestones, including the development of a multimodal AI platform that combines computational data with wet lab biological data. This has positioned 1910 Genetics as a critical partner for leading pharma and tech companies, enhancing their drug discovery capabilities and advancing their internal pipeline, particularly in neurological diseases.
GEn1E Lifesciences
gen1e.com

Verge Genomics
vergegenomics.com

WhiteLab Genomics
whitelabgx.com

NeuroX1
neurox1.com

Insitro
insitro.com

Probably Genetic

Harmonic Discovery

Generate Biomedicines

Anagenex
anagenex.com

Diffuse Bio
diffuse.bio

PostEra
postera.ai

Sequence Bio
sequencebio.com

GeneCentrix
genecentrix.com

DeepCure
deepcure.ai

Cognaisent
cognaisent.com
Companies similar to 1910 include GEn1E Lifesciences, Verge Genomics, WhiteLab Genomics and NeuroX1.
1910 was founded in 2018.
1910's headquarters is located in Cambridge, MA, US.
1910's most recent funding round was for $550k (USD) in September 2021.
As of Sep 30, 2021, 1910 has raised a total of $26.8M (USD).
1910 has 22 employees as of Feb 5, 2024.